1. Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine
   C. Rory Goodwin et al, 2016, SPINE CrossRef
2. Investigation of the molecular mechanisms underlying metastasis in prostate cancer by gene expression profiling.
   Xinghua Zhang et al, 2016, Exp Ther Med CrossRef
3. Chrysin induces death of prostate cancer cells by inducing ROS and ER stress
   Soomin Ryu et al, 2017, J Cell Physiol CrossRef
4. Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activity
   Marius Mioc et al, 2017 CrossRef
5. Statin derivatives as therapeutic agents for castration-resistant prostate cancer
   Matthew A. Ingersoll et al, 2016, Cancer Letters CrossRef
6. Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer
   Johnny R. Ramroop et al, 2018, Front. Oncol. CrossRef
7. Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K/Akt pathway
   Jianwei Zhu et al, 2018, Cell Death Dis CrossRef
8. Synthesis and PI3 Kinase Inhibition Activity of a Wortmannin-Leucine Derivative
   William Cantrell et al, 2018, Molecules CrossRef
9. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy
   Yogesh M. Bramhecha et al, 2018, Mod Pathol CrossRef
10. A short peptide reverses the aggressive phenotype of prostate cancer cells
    Hongjiao Liu et al, 2018, European Journal of Pharmacology CrossRef
11. Isolation, Characterization and Antitumor Effect on DU145 Cells of a Main Polysaccharide in Pollen of Chinese Wolfberry
    Fei Chen et al, 2018, Molecules CrossRef
12. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma
    Nada M. S. Al-Saffar et al, 2018, Br J Cancer CrossRef
13. Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways
    Whasun Lim et al, 2017, J. Cell. Biochem. CrossRef
14. PROSTAGLANDIN E₂ stimulates cancer-related phenotypes in prostate cancer PC3 cells through cyclooxygenase-2.
    Antonio Madrigal-Martínez et al, 2019, J Cell Physiol CrossRef
15. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy
    Brian Olson et al, 2018, Urologic Oncology: Seminars and Original Investigations CrossRef
16. Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
    Marianna A. Zolotovskaia et al, 2019, Front. Pharmacol. CrossRef
17. Upstream regulators of phosphoinositide 3-kinase and their role in diseases
    Dandan Wang et al, 2019, J Cell Physiol CrossRef
18. Complex Systems Biology Approach in Connecting PI3K-Akt and NF-κB Pathways in Prostate Cancer
    Eswar Shankar et al, 2019, Cells CrossRef
19. Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics
    Kai Wu et al, 2019, Cancer Cell Int CrossRef
20. ABT-737 and erufosine combination against castration-resistant prostate cancer
    Ezgi Avsar Abdik et al, 2019, Anti-Cancer Drugs CrossRef
21. Targeting of SPP1 by microRNA‐340 inhibits gastric cancer cell epithelial–mesenchymal transition through inhibition of the PI3K/AKT signaling pathway
    Su‐Zhen Song et al, 2019, J Cell Physiol CrossRef
22. The current evidence on statin use and prostate cancer prevention: are we there yet?
    Mahmoud A. Alfaqih et al, 2017, Nat Rev Urol CrossRef
23. The Oncogene IARS2 Promotes Non-small Cell Lung Cancer Tumorigenesis by Activating the AKT/MTOR Pathway
    Xin Di et al, 2019, Front. Oncol. CrossRef
24. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling
    Guang Yan et al, 2019, Cell Commun Signal CrossRef
25. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis
    Ming-Hsien Chien et al, 2019, J Exp Clin Cancer Res CrossRef
26. Knockdown of TMPRSS11D inhibits the proliferation, migration and invasion of cervical cancer cells
    Kun Yan et al, 2019, RSC Adv. CrossRef
27. Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects
    Yoko Omoto et al, 2015, Cancer Sci CrossRef
28. The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases
    Fabio Cofano et al, 2019, Cancer Control CrossRef
29. Global Conservation of Protein Status between Cell Lines and Xenografts
    Julian Biau et al, 2016, Translational Oncology CrossRef
30. IL-7/IL-7 receptor axis stimulates prostate cancer cell invasion and migration via AKT/NF-κB pathway
    Hu Qu et al, 2016, International Immunopharmacology CrossRef
31. The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth
    Rayna Rosati et al, 2016, J. Biol. Chem. CrossRef
32. Inhibiting PI3K-AKt signaling pathway is involved in antitumor effects of ginsenoside Rg3 in lung cancer cell
    Qipeng Xie et al, 2017, Biomedicine & Pharmacotherapy CrossRef
33. Docetaxel Combined with Thymoquinone Induces Apoptosis in Prostate Cancer Cells via Inhibition of the PI3K/AKT Signaling Pathway
    Santosh Kumar Singh et al, 2019, Cancers CrossRef
34. Plasma microRNA signature is associated with risk stratification in prostate cancer patients
    Abeer Al-Qatati et al, 2017, Int. J. Cancer CrossRef
35. Prostate cancer, PI3K, PTEN and prognosis.
    Helen M Wise et al, 2017, Clin Sci (Lond) CrossRef
36. null
    Marianna Zolotovskaia et al, 2020 CrossRef
37. Coix lacryma-jobi var. ma-yuen Stapf sprout extract induces cell cycle arrest and apoptosis in human cervical carcinoma cells
    Eun Suk Son et al, 2019, BMC Complement Altern Med CrossRef
38. Gene set based systematic analysis of prostate cancer and its subtypes
    Senlin Ye et al, 2019, Future Oncology CrossRef
39. null
    Chenchu Lin et al, 2019 CrossRef
40. Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents
    Yueqin Yang et al, 2020, Molecules CrossRef
41. Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients
    Verena Lieb et al, 2018, Oncotarget CrossRef
42. STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo
    Torstein Lindstad et al, 2017, Oncotarget CrossRef
43. β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation
    Aejaz Sayeed et al, 2016, Oncotarget CrossRef
44. Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy
    Fan Xu et al, 2016, Oncotarget CrossRef
45. null
    John Berry-Candelario et al, 2020 CrossRef
46. Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.
    Monyse de Nóbrega et al, 2020, Genet Mol Biol CrossRef
47. Prostate-specific antigen modulates the osteogenic differentiation of MSCs via the cadherin 11-Akt axis
    Longxiang Wu et al, 2020, Clin. Transl. Med. CrossRef
48. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Boris Y Shorning et al, 2020, Int J Mol Sci CrossRef
49. In silico docking of phytocompounds to identify potent inhibitors of signaling pathways involved in prostate cancer
    Bhavana Jonnalagadda et al, 2020, Journal of Biomolecular Structure and Dynamics CrossRef
50. Asparaginyl endopeptidase enhances pancreatic ductal adenocarcinoma cell invasion in an exosome-dependent manner and correlates with poor prognosis
    Qiang Yan et al, 2018, Int J Oncol CrossRef
51. Gambogic acid suppresses colon cancer cell activity in vitro
    Zailong Zhou et al, 2019, Exp Ther Med CrossRef
52. Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met.
    Yan Shu et al, 0 CrossRef
53. AQP9 promotes astrocytoma cell invasion and motility via the AKT pathway
    Yao Lv et al, 2018, Oncol Lett CrossRef
54. A meta‑analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR‑193a‑5p in lung cancer
    Zu‑Cheng Xie et al, 2018, Oncol Lett CrossRef
55. Crocetin attenuates the oxidative stress, inflammation and apoptosis in arsenic trioxide-induced nephrotoxic rats: Implication of PI3K/AKT pathway
    Panpan Liu et al, 2020, International Immunopharmacology CrossRef
56. Three-Dimensional Cell Cultures as an In Vitro Tool for Prostate Cancer Modeling and Drug Discovery
    Fabrizio Fontana et al, 2020, IJMS CrossRef
57. Deletion of NKX3.1 via CRISPR/Cas9 Induces Prostatic Intraepithelial Neoplasia in C57BL/6 Mice
    Jin Ju Park et al, 2020, Technol Cancer Res Treat CrossRef
58. Mechanisms of docetaxel resistance in prostate cancer: the key role played by miRNAs
    Milena Rizzo, 2020, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
59. CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis
    Ozel Capik et al, 2021, Prostate Cancer Prostatic Dis CrossRef
60. Identification of miRNA-Mediated Subpathways as Prostate Cancer Biomarkers Based on Topological Inference in a Machine Learning Process Using Integrated Gene and miRNA Expression Data
    Ziyu Ning et al, 2021, Front. Genet. CrossRef
61. ENHANCED ANTICANCER POTENCY OF GEMCITABINE IN COMBINATION WITH PROPOFOL IN PROSTATE CANCER
    Elanur AYDIN KARATAŞ et al, 2021 CrossRef
62. Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
    Tomoyuki Makino et al, 2021, Biomedicines CrossRef
63. Improving Strategies in the Development of Protein‐Downregulation‐Based Antiandrogens
    Rongyu Zhang et al, 2021, ChemMedChem CrossRef
64. TRIB3 promotes proliferation, migration, and invasion of retinoblastoma cells by activating the AKT/mTOR signaling pathway.
    Xian-Yi Bao et al, 2021, Cancer Biomark CrossRef
65. A Bioinformatic Investigation of the Mechanism Underlying Migraine-Induced Erectile Dysfunction
    Ji-sheng Wang et al, 2021, BioMed Research International CrossRef
66. Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
    Zoe R Maylin et al, 2021, Translational Oncology CrossRef
67. Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review
    Elena Ferrari et al, 2021, IJMS CrossRef
68. Identification of ARHGEF38, NETO2, GOLM1, and SAPCD2 Associated With Prostate Cancer Progression by Bioinformatic Analysis and Experimental Validation.
    Zhuolun Sun et al, 2021, Front Cell Dev Biol CrossRef
69. Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K/Akt pathway.
    Shan Zhu et al, 2021, Life Sci CrossRef
70. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
    Thanakorn Pungsrinont et al, 2021, IJMS CrossRef
71. null
    Surayya Siddiqui et al, 2021 CrossRef
72. Genetics of prostate cancer and its utility in treatment and screening.
    S Benafif et al, 2021, Adv Genet CrossRef
73. null
    Abhishek Bardhan et al, 2022 CrossRef
74. Clinical values of expression signature of circCDR1AS and circHIAT1 in prostate cancer: Two circRNAs with regulatory function in androgen receptor (AR) and PI3K/AKT signaling pathways
    Mahsa Aghajani Mir et al, 2022, Clinical Laboratory Analysis CrossRef
75. Protective effect of α-mangostin derivatives on hypoxia/reoxygenation-induced apoptosis in H9C2 cells and their mechanism
    Yan Zhao et al, 2022, Phytochemistry Letters CrossRef
76. mTOR Signaling and Potential Therapeutic Targeting in Meningioma
    Benjamin Pinker et al, 2022, IJMS CrossRef
77. Telmisartan anti‐cancer activities mechanism through targeting N‐cadherin by mimicking ADH‐1 function
    Marjan Khorsand et al, 2022, J Cellular Molecular Medi CrossRef
78. The Promising Therapeutic and Preventive Properties of Anthocyanidins/Anthocyanins on Prostate Cancer
    Javad Mottaghipisheh et al, 2022, Cells CrossRef
79. Lysine demethylase 5A promotes prostate adenocarcinoma progression by suppressing microRNA-330-3p expression and activating the COPB2/PI3K/AKT axis in an ETS1-dependent manner
    Yuanyuan Mi et al, 2022, J. Cell Commun. Signal. CrossRef
80. Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
    SongYang Yiyan et al, 2022, CCDT CrossRef
81. Effect of MicroRNA-210 on the Growth of Ovarian Cancer Cells and the Efficacy of Radiotherapy
    Yinlong Zhao et al, 2021, Gynecol Obstet Invest CrossRef
82. Fibronectin Modulates the Expression of miRNAs in Prostate Cancer Cell Lines
    Bruno Martinucci et al, 2022, Front. Vet. Sci. CrossRef
83. Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer
    Nikita Jinna et al, 2022, IJMS CrossRef
84. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer
    Renjith P. Johnson et al, 2022, Drug Resistance Updates CrossRef
85. Nephroprotective potential of eugenol in a rat experimental model of chronic kidney injury; targeting NOX, TGF-β, and Akt signaling
    Moustafa Fathy et al, 2022, Life Sciences CrossRef
86. Mechanisms of solid lipid nanoparticles-triggered signaling pathways in eukaryotic cells
    Thaís Lacerda et al, 2022, Colloids and Surfaces B: Biointerfaces CrossRef
87. null
    Abhishek Bardhan et al, 2022 CrossRef
88. A LETM2-Regulated PI3K-Akt Signaling Axis Reveals a Prognostic and Therapeutic Target in Pancreatic Cancer
    Shurui Zhou et al, 2022, Cancers CrossRef
89. Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation
    Emeline I J Lelong et al, 2022 CrossRef
90. Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network
    Jiannan Yang et al, 2022 CrossRef
91. Multifaceted Function of MicroRNA-299-3p Fosters an Antitumor Environment Through Modulation of Androgen Receptor and VEGFA Signaling Pathways in Prostate Cancer
    Kavya Ganapathy et al, 2020, Sci Rep CrossRef
92. Mitochondrial respiration inhibitor enhances the anti-tumor effect of high-dose ascorbic acid in castration-resistant prostate cancer
    Jia Qiu et al, 2022, J Mol Med CrossRef
93. Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?
    Javier Pozas et al, 2022, Cancers CrossRef
94. Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma
    Qiong-Ying Hu et al, 2023, Molecules CrossRef
95. Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer
    Tina Petrić et al, 2023, IJMS CrossRef
96. Cancer stem cell in prostate cancer progression, metastasis and therapy resistance.
    Poornima Verma et al, 2023, Biochim Biophys Acta Rev Cancer CrossRef
97. Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
    Belén Congregado Ruiz et al, 2023, Biomedicines CrossRef
98. Instrumental and transcriptome analysis reveals the chemotherapeutic effects of doxorubicin-loaded black phosphate nanosheets on abiraterone-resistant prostate cancer
    Haoyang Xu et al, 2023, Bioorganic Chemistry CrossRef
99. Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?
    Cheng Zha et al, 2023, Front Oncol CrossRef
100. Ginsenosides in cancer: Targeting cell cycle arrest and apoptosis.
     Muhammad Ajmal Shah et al, 2023, Chem Biol Interact CrossRef
101. EGFR‐mediated hyperacetylation of tubulin induced docetaxel resistance by downregulation of HDAC6 and upregulation of MCAK and PLK1 in prostate cancer cells
     Yeong‐Shiau Pu et al, 2023, The Kaohsiung J of Med Scie CrossRef
102. Unveiling genetic variant-level biomarkers for aggressive prostate cancer
     Tasnimul Alam Taz et al, 2023, Informatics in Medicine Unlocked CrossRef
103. Fucoidan’s Molecular Targets: A Comprehensive Review of Its Unique and Multiple Targets Accounting for Promising Bioactivities Supported by In Silico Studies
     Ahmed Zayed et al, 2023, Marine Drugs CrossRef
104. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer
     Hannah E. Bergom et al, 2024, npj Genom. Med. CrossRef
105. Cholesterol metabolism: physiological regulation and diseases
     Jiarui Guo et al, 2024, MedComm CrossRef
106. Microbiome Dysbiosis Is Associated with Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer
     Matthew Uzelac et al, 2024, IJMS CrossRef
107. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies
     Rupali Mohite et al, 2024, CCDT CrossRef
108. Inhibition of Prostate Cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of Akt and Activation of AMPK Signaling
     Matteo Nadile et al, 2024, Nutrients CrossRef
109. GPC2 promotes prostate cancer progression via MDK-mediated activation of PI3K/AKT signaling pathway
     Sijin Chen et al, 2024, Funct Integr Genomics CrossRef
110. Pleckstrin-2 mediates the activation of AKT in prostate cancer and is repressed by androgen receptor
     Xu Han et al, 2024, The American Journal of Pathology CrossRef
111. Network pharmacology and experimental validation to explore the role and potential mechanism of Liuwei Dihuang Decoction in prostate cancer
     Xiangyang Zhan et al, 2024, BMC Complement Med Ther CrossRef
112. LncRNA NONHSAT227443.1 Confers Esophageal Squamous Cell Carcinoma Chemotherapy Resistance by Activating PI3K/AKT Signaling via Targeting MRTFB
     Yuchen Wang et al, 2024, Technol Cancer Res Treat CrossRef
113. Novel Mutations in AKT1 Gene in Prostate Cancer Patients in Jordan
     Ala’a Alasmar et al, 2024, CIMB CrossRef
114. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition
     Yu Chang et al, 2024, Cell Reports Medicine CrossRef
115. 1,4-Naphthoquinone thiazoles: Synthesis, crystal structure, anti-proliferative activity, and inverse molecular docking study
     Cagla Efeoglu et al, 2024, Journal of Molecular Structure CrossRef
116. PI3K/AKT/mTOR Targeting in Colorectal Cancer Radiotherapy: A Systematic Review
     SN Mousavikia et al, 2025, J Gastrointest Canc CrossRef